The independent Eppendorf Award Jury has selected Prof. Dr. Randall J. Platt, Assistant Professor of Biological Engineering, ETH Zurich, Switzerland, as the 2020 winner of the Eppendorf Award for Young European Investigators.

Carterra® Inc. and La Jolla Institute for Immunology (LJI) have announced that they will use Carterra’s proprietary LSA™ platform to screen hundreds of antibodies in just a few days.

Cobra Biologics has announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19 (ChAdOx1), for fast-tracked clinical trials for COVID-19.

Amoéba has announced the signature of a Material Transfer Agreement (MTA) with Certis Europe; the purpose of the research partnership is the delivery by Amoéba of experimental biocontrol products for crop protection.

Cherwell Laboratories have introduced the new SAS Super Pinocchio CR to their range of microbial air samplers.

Cobra and the Karolinska Institutet have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium.

ENPICOM has announced a major release of its ImmunoGenomiX (IGX) Platform, designed to streamline the analysis and management of vast amounts of repertoire sequencing data, accelerating the discovery and development of new biological targets.

In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics Inc. (SmartPharm) announced a research and development collaboration to develop a next-generation, gene-encoded antibody vaccine for COVID-19.

FDA grants emergency use authorization for fastest available molecular point-of-care test for novel coronavirus.

N4 Pharma has announced that it will be undertaking a proof of concept research project using a COVID-19 DNA plasmid for the purpose of demonstrating the ability of Nuvec® to be used as a delivery system by potential collaboration partners developing COVID-19 DNA or RNA vaccines.